In Vivo Emergence of Pandrug-Resistant Acinetobacter baumannii Strain: Comprehensive Resistance Characterization and Compassionate Use of Sulbactam-Durlobactam

The treatment of patients with infection secondary to carbapenem-resistant Acinetobacter baumannii with emerging cefiderocol resistance remains challenging and unclear. We present a case of in vivo emergence of pandrug-resistant A baumannii that was successfully treated with the compassionate use of investigational sulbactam-durlobactam-based antibiotic regimen. We also performed a longitudinal genomic analysis of the bacterial isolates and showed the development of resistance and genetic mutations over time.

Automated summary

The treatment of carbapenem-resistant Acinetobacter baumannii infection with emerging cefiderocol resistance remains challenging. This study presented a case of in vivo emergence of pandrug-resistant A baumannii that was successfully treated with investigational sulbactam-durlobactam-based antibiotic regimen. Longitudinal genomic analysis showed the development of resistance and genetic mutations over time.